EDT talks about the contract manufacturing market at Interphex

By Gareth Macdonald

- Last updated on GMT

Related tags Contract manufacturing Manufacturing

Pharma industry demand for outsourced manufacturing is growing and will favour larger contracting players according to Elan Drug Technologies (EDT).

Outsourcing-pharma.com spoke with EDT’s Philip Pratten at Interphex 2011 to find out about the state of the market in six months​ since the firm launched its contract manufacturing services.

Pratten explained that the market is dynamic with reorganisation of the pharmaceutical sectors manufacturing base and search for more ‘strategic partnerships’ creating buoyant demand, at least from EDT’s perspective.

He went on to suggest that this, in part at least, is being driven by EDT’s track record in delivery technologies, which is attractive to a drug industry keen to make manufacturing as cost effective as possible.

The kind of business that they [pharmacaceutical customers] are asking for are real solutions, perhaps using a proprietary Elan technology​,” Pratten explained, adding that customers also the firm’s experience in working with difficult to deliver molecules.

Pratten also shared his thoughts on the future of the contract manufacturing industry, adding that: “It’s going to take strong, larger players to support the kind of outsourcing demands of the future​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers